NIBRT Scientist Leads Program for Single-Cell Analysis Research
Colin Clarke, from the National Institute for Bioprocessing Research and Training, will lead a four-year European Industrial Doctoral Program for enhancing upstream biopharmaceutical manufacturing process development through single cell analysis.
The National Institute for Bioprocessing Research and Training (NIBRT) announced in a Sept. 17, 2018 press release that a four-year doctoral training and research program focusing on enhancing upstream biopharmaceutical manufacturing process development through single-cell analysis would be led by its one of its researchers, Dr. Colin Clarke. The competitive European Industrial Doctorate (EID) program is funded by the Marie SkÅodowska-Curie Actions program of Horizon 2020. Clarke ‘s team will collaborate with scientists across Europe in the €2.9 million (USD 3.4 million) project, which will begin in 2019.
Overcoming the inherent heterogeneity of cells grown in vitro to deliver effective, uniform, and safe biological medicines is one of the most significant challenges faced by the industry today, according to the press release. The STACCATO research program will develop single-cell analysis methods to characterize the molecular heterogeneity of cell populations used in the biopharmaceutical industry.
“We’re delighted that Colin will lead this program to develop the next generation of early-stage researchers. A key feature of STACCATO is collaboration amongst experts in the production of different biopharmaceuticals which provide highly encouraging clinical outcomes,” said Dominic Carolan, NIBRT CEO, in the release.
Source: NIBRT
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 1st 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
August 1st 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
